Trial reportBritish journal of clinical pharmacology2010
Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting.
Trial report in British journal of clinical pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 11 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Cannabinoids for the prevention of chemotherapy-induced nausea and vomiting in oncological therapy: a systematic review.Journal of cancer survivorship : research and practice · 2026Pooled it
- Indications of Cannabinoids for the Palliation of Cancer-Associated Symptoms: A Systematic Review and Meta-Analysis.Current oncology reports · 2025Pooled it
- Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- Adverse events caused by cannabinoids in middle aged and older adults for all indications: a meta-analysis of incidence rate difference.Age and ageing · 2024Pooled it
- MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse events.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Guideline
- Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.BMC medicine · 2022Pooled it
- Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis.PLoS medicine · 2021Pooled it
- Pharmacological evidence of medicinal cannabis in oncology: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Pooled it
- Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.The Cochrane database of systematic reviews · 2015Pooled it
- Marijuana use and motor vehicle crashes.Epidemiologic reviews · 2012Pooled it
- A Systematic Review on Cannabis Hyperemesis Syndrome and Its Management Options.Medical principles and practice : international journal of the Kuwait University, Health Science CentrePooled it
- Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and Permeation Enhancement.AAPS PharmSciTech · 2026Review
- Cannabinoids in oncology: pharmacology, clinical applications, and translational perspectives.Frontiers in pharmacology · 2026Review
- The Role of Cannabinoids and the Endocannabinoid System in the Treatment and Regulation of Nausea and Vomiting.Current topics in behavioral neurosciences · 2026Review
- Nanotechnology for the Efficacious Delivery of Medicinal Cannabis and Pharmaceutical Medicines.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Adverse events associated with the use of cannabis-based products in people living with cancer: a systematic scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Hemp Extract (Pharmaceuticals (Basel, Switzerland) · 2024Article
- The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine.Current oncology reports · 2024Review
- Cannabinoid combination targetseLife · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsDespite progress in anti-emetic treatment, many patients still suffer from chemotherapy-induced nausea and vomiting (CINV). This is a pilot, randomized, double-blind, placebo-controlled phase II clinical trial designed to evaluate the tolerability, preliminary efficacy, and pharmacokinetics of an acute dose titration of a whole-plant cannabis-based medicine (CBM) containing delta-9-tetrahydrocannabinol and cannabidiol, taken in conjunction with standard therapies in the control of CINV.
methodsPatients suffering from CINV despite prophylaxis with standard anti-emetic treatment were randomized to CBM or placebo, during the 120 h post-chemotherapy period, added to standard anti-emetic treatment. Tolerability was measured as the number of withdrawals from the study during the titration period because of adverse events (AEs). The endpoint for the preliminary efficacy analysis was the proportion of patients showing complete or partial response.
resultsSeven patients were randomized to CBM and nine to placebo. Only one patient in the CBM arm was withdrawn due to AEs. A higher proportion of patients in the CBM group experienced a complete response during the overall observation period [5/7 (71.4%) with CMB vs. 2/9 (22.2%) with placebo, the difference being 49.2% (95% CI 1%, 75%)], due to the delayed period. The incidence of AEs was higher in the CBM group (86% vs. 67%). No serious AEs were reported. The mean daily dose was 4.8 sprays in both groups.
conclusionCompared with placebo, CBM added to standard antiemetic therapy was well tolerated and provided better protection against delayed CINV. These results should be confirmed in a phase III clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.